Labinaz, M.

patient study outcome cabg patients death group 180 days 30 days mortality valve baseline aortic trial characteristic follow-up heart treatment disease baseline characteristics difference artery signi result signi ficantly mortality rate event 2 years elevation infarction syndrome /iiia eptifibatide history vessel graft circulation surgery angina table pursuit platelet investigator university revascularization procedure cardiol non-st-segment elevation acs effect 30- prior-pci patients survival culprit vessel ck-mb concentration randomization figure 0.001 labinaz receptor suppression corevalve integrilin therapy culprit ficantly glycoprotein therapy aortic valve stenosis ficant implantation stenosi intervention st-segment elevation coll cardiol prior-pci 1.00 enrolment non-st-segment hazard buellesfeld ottawa heart institute 2- year follow-up moderate-risk